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مضاعفات العني عند املصابني باجلذام يف اليمن
 رجا عبده اأحمد �صامل
امللخ�ض: الهدف: حتديد امل�صاعفات الرئي�صية التي تهدد العني والب�رص والناجمة عن مر�ض اجلذام يف اليمن. الطريقة: اأجريت هذه الدرا�صة 
املقطعية خالل الفرتة من فرباير 2010 حتى يوليو 2010 و�صملت املر�صى الذين ترددوا على م�صت�صفى االأمرا�ض اجللدية والتنا�صلية يف 
مدينة النور مبدينة تعز )اليمن( من قبل اأخ�صائي عيون وذلك بعد اأخد موافقتهم. مت اأخذ التفا�صيل الدميوغرافية والطبية لكل مري�ض مع 
فح�ض دقيق للعني �صامال فح�ض حّدة الب�رص، وفح�ض امل�صباح ال�صقي، وفح�ض قاع العني على كل مري�ض من قبل طبيب عيون موؤهل. 
النتائج: �صملت الدرا�صة 192 مري�صا )180 رجال و 12 امراأة ( بن�صبة تقدر1:15 للرجال اإىل الن�صاء . كان عمر معظم املر�صى )157 - 
%81.8 ( فوق االأربعني عاما، واأكرث من ُثُلثي املر�صى )129 - %67.2( كانوا يعانون من مر�ض اجُلذام الأكرث من 20 عاما. وجدنا 
ٍ)150 - %39.1( من العيون اإ�صابة مبر�ض واحد على االأقل. كانت اإ�صابة اجلفون  م�صاعفات العيون يف )%97( من احلاالت، ويف 
مبر�ض اجلذام االأكرث �صيوعا )102 - %26.5(. وكانت قوة االإب�صار اأقل من 60/6 يف )192 - %50(، كما كانت عتامة القرنية من اأكرث 
االأ�صباب املوؤدية للعمى )69 - %35.9(. اخلال�صة: م�صاعفات العيون الناجتة عن مر�ض اجلذام منت�رصة يف اليمن، وهي تهدد بفقدان 
الب�رص. من ال�رصوري منع حدوث هذه امل�صاعفات بوا�صطة الت�صخي�ض املبكر والعالج املنا�صب.
مفتاح الكلمات: جذام، عمى، عتامة القرنية، جفون العني، اليمن.
abstract: Objectives: This study was conducted to identify the main ocular- and vision-threatening complications 
of leprosy in Yemen. Methods: This is a cross-sectional observational study which took place from February to July 
2010. Leprosy patients attending the Skin and Venereal Diseases Hospital in the City of Light in Taiz, Yemen, who 
consented to participate in the study, were enrolled. Detailed demographic and medical histories were taken and 
clinical examination findings were recorded. A detailed eye examination, including visual acuity (VA), slit-lamp, 
and fundus examinations, was conducted on each patient by a qualified ophthalmologist. Results: A total of 192 
patients (180 male, 12 female, with a male to female ratio of 15:1) were included in the study. The majority of the 
patients (157; 81.8%) were over 40 years. Over two-thirds of the patients (129; 67.2%) had had leprosy for more 
than 20 years. Ocular complications were found in 97% of cases; 150 (39.1%) of the patients’ eyes had at least one 
pathology. Eyelid involvement was the most common problem observed in 102 (26.5%) patients. Half of the eyes 
(192; 50%) had a VA of <6/60. The main cause of blindness among these patients was corneal opacity detected in 69 
out of 192 patients (35.9%). Conclusion: Ocular complications are frequent among leprosy patients in Yemen. They 
are true vision-threatening lesions. It is important to prevent these lesions through early diagnosis and adequate 
treatment.
Keywords: Leprosy; Blindness; Corneal opacity; Eyelid; Yemen.
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Advances in Knowledge
- This is the first study of its kind in Yemen that reports ocular complications among leprosy patients.  
- Ocular complications of leprosy are a social and economic burden but these debilitating diseases are largely preventable in those with 
leprosy.
 Application to Patient Care
- This study highlights the importance of regular ophthalmic exams and of providing appropriate and early treatment for leprosy patients 
in order to prevent avoidable blindness.
- Medical and paramedical personnel should be aware of leprosy and its ocular complications.
- The study emphasises the importance of promoting and improving ophthalmic services to leprosy patients. 
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Leprosy is a chronic infectious disease caused by mycobacterium leprae, or Hansen's bacillus. This disease, which 
is as old as humanity, is always terrifying because 
it mutilates, disfigures, and causes blindness.1 It 
may affect the eye through infection of the skin of 
the lids, tear ducts, or the lacrimal glands; it may 
also involve the facial and ophthalmic division 
of the trigeminal nerve, or direct invasion of the 
anterior segment, or sensitisation of the tissue to 
M. leprae.2–6 
Known as gutham in Arabic, the history of 
leprosy in Yemen dates back to AD 747 when 
the then ruler, the Abbasid Wali, M.Z. Abou-
Al-Madan, collected huge quantities of wood 
to burn the leprosy patients in Sana'a as a way of 
eradicating this problem; however, he died before 
he could carry out this act.7 These well-documented 
events in Yemen’s history clearly demonstrate the 
social stigma attached to leprosy. Over-crowding, 
unhygienic living conditions, and malnutrition are 
considered principal causes of the endemicity of 
leprosy.
Before 1964, leprosy patients in most parts of 
Yemen were subjected to obligatory isolation in 
unsanitary houses.8 Clinics in Aden, Sana'a, Taiz, 
and Mukalla were the only places providing very 
basic medical care for lepers. From 1974, leprosy 
work in Yemen was carried out by the Missionaries 
of Charity. In 1982, Dr. Al-Qubati took up the 
duties at the Skin and Venereal Disease Hospital in 
the City of Light, Taiz, which was the only referral 
hospital in the country for the treatment of leprosy 
and its complications at that time.9 In 1991, the 
Missionaries of Charity left the service of the leper 
colonies and the National Leprosy Control Program 
(NLCP) and under the jurisdiction of the Ministry 
of Public Health took over that responsibility. The 
NLCP currently provides services to 80% of the 
country.9
In Yemen, leprosy patients are isolated, 
excluded, and even abandoned by families and 
society. Yemen’s leprosy caseload has declined from 
a peak of 2,314 patients registered for multidrug 
therapy (MDT) in 1989 to 765 patients registered 
in 1996. Moreover, the registered prevalence of 
leprosy sufferers had declined from 1.9 per 10,000 
in 1989 to 0.5 per 10,000 in 1996.10
Although leprosy control has been a public 
health success over the past decades, leprosy 
patients still suffer from avoidable blindness. 
Worldwide, an estimated 200,000–300,000 leprosy 
patients are blind.11 Many of them could have been 
spared this dreaded outcome by early detection and 
treatment of eye involvement through patient and 
physician education and awareness. 
Blindness for leprosy patients is disastrous 
as they depend on their vision to protect their 
limbs from the injuries and burns that are due to 
the numbness and loss of sensation caused by the 
disease. This visual disability is to a large extent 
preventable, provided that the ocular involvement 
is diagnosed at an early stage and appropriate 
measures are undertaken in time. Globally, many 
studies have been carried out on the ocular 
complications of leprosy;12,13 however, in Yemen 
these complications have never been documented 
or reported. Therefore, this study was conducted to 
determine the main ocular findings, the presence of 
vision-threatening eye conditions, and the causes 
of visual impairments and blindness among leprosy 
patients in Yemen. This information will allow 
the establishment of a plan for eye care services 
through leprosy control and blindness prevention 
programmes.
Methods
This was a cross-sectional observational study, 
which was conducted from February to July 2010. 
Approval of the Research and Ethics Committee 
of the University of Aden, Faculty of Medicine 
& Health Sciences, was granted retrospectively 
in January 2011. A total of 192 leprosy patients 
(irrespective of the type of leprosy), who attended 
the Skin and Venereal Diseases Hospital located 
at the City of Light in Taiz, were examined. After 
explaining the purpose of the study, verbal consent 
was obtained. Some of the patients were still on 
MDT while others had already been released 
from treatment. Individuals’ data on age, sex, and 
duration of the disease were recorded, and a short 
history taken regarding eye complications. Patients 
were first observed for any obvious facial or ocular 
deformities and visual acuity (VA) was assessed 
using a Snellen or tumbling E chart at 6 metres. An 
eye was considered to be severely disabled or blind 
when VA was <6/60. A torch light examination 
was done to determine eyelid position, and pupil 
size, shape, and reaction. The patients were then 
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subjected to slit lamp biomicroscopy. Thereafter, the 
pupils were dilated using tropicamide 1% eye drops, 
and a fundus examination was done by a qualified 
ophthalmologist using a direct ophthalmoscope. 
Intraocular pressure was recorded using a Schiotz 
tonometer and corneal sensation was checked with 
a tuft of cotton. A visual field test was not done. 
Data were analysed using Statistical Package 
for the Social Sciences (SPSS), Version 17, (IBM, 
Chicago, Illinois, USA). Descriptive statistics 
was done with a frequency distribution and a 
95% confidence interval (CI). The chi-square and 
Fischer exact probability tests were used to test 
the association between ocular findings and the 
affected eye with a P value of <0.05 considered the 
cut-off point for statistical significance.  
Results
A total of 192 leprosy patients were enrolled in 
this study, 180 (93.8%) males and 12 (6.2%) female 
patients, with a male to female ratio of 15:1. The age 
range was 22–77 years (mean + standard deviation 
(SD) = 55.4 ± 12.5 years). The majority of patients 
(157; 81.8%) were over 40 years old. The mean 
duration of the disease varied from 1–50 years 
(SD = 22.1 ± 10.3 years). More than two-thirds 
(129; 67.2%) had had the disease for more than 20 
years, the duration being derived from patients’ 
statements.
Out of 384 eyes examined, 150 (39.1%) had 
at least one pathology, with many eyes (57.6%) 
exhibiting more than one lesion. Table 1 shows the 
major ocular lesions detected in these 192 patients 
as follows: eyelid involvement (trichiasis, entropion, 
madarosis) (26.5%); lagophthalmos (23%); corneal 
opacity (21.9%); uveitis (20%), and cataracts (14%). 
A total of 50% (192 eyes) were determined to have 
a VA of <6/60. Four lesions were encountered, with 
a higher frequency in the left eye as compared 
to the right. However, a statistically significant 
difference was detected for uveitis (P = 0.02); 
retinal lesions (Fisher exact probability [FEP]) = 
0.0002), and phthisis bulbi (FEP = 0.03). The right 
eye was affected with lid lesions and lagophthalmos 
more commonly than the left. The difference 
was statistically significant for lagophthalmos 
(P = 0.0005). Age, duration of disease, and ocular 
findings in leprotic patients are shown in Table 2. 
A higher percentage of ocular findings were found 
in patients of >40 years (69.5%), and in those having 
had leprosy for >20 years (55.5%).
Patients with a VA of <6/60 underwent a detailed 
examination to evaluate the cause of blindness. 
Table 3 shows the prevalence of blindness in 
different leprotic lesions. Sixty-nine eyes (35.9%) 
were blind due to corneal opacity, whereas 60 eyes 
(31.3%) had cataracts, and 45 (23.4%) were blind 
 Table 1: Ocular findings in leprosy patients








Lid involvement 54 48 102 (26.5) 0.48 
0.488
Lagophthalmos 60 30 90 (23.0) 13.06 
 0.001
Corneal opacity 42 42 84 (21.9) 0.00 
1.00
Uveitis 30 48 78 (20.0) 5.21 
0.02
Cataract 24 30 54 (14.0) 0.78  
0.378
Retinal lesions 0 12 12 (3.0) 0.001
Phthisis bulbi 0 6 6 (1.6) 0.03
VA <6/60 90 102 102 (50%) 1.50 
0.2206
FEP = Fisher exact probability; * = statistically significant; VA = visual acuity 
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because of uveitis. Thirty-seven (19%) patients had 
binocular blindness. Table 4 gives a summary of the 
ocular pathologies and main causes of blindness in 
different studies of leprosy.
Discussion
This study, the first of its kind in Yemen, identified the 
main ocular- and vision-threatening complications 
of leprosy. Ocular complications were found in 97% 
of cases studied. Over one-third of the patients’ eyes 
had at least one pathology. Eyelid involvement was 
the most common problem observed. Half of the 
eyes had a VA of <6/60. The main cause of blindness 
among these patients was corneal opacity detected 
in more than a third of patients.
Most of the world's leprosy sufferers live in 
developing countries where the prevalence of 
many other diseases is high and medical care 
is very limited. Generally, patients suffer from 
stigmatisation, which is an experience common to 
leprosy patients in all societies, and this limits their 
use of the scarce medical services that are available. 
Unfortunately, the resulting delays in treatment 
worsen long-term outcomes. 
Many studies that have dealt with leprosy 
either in Yemen or in its neighbouring Gulf 
Cooperation Council (GCC) countries have been 
epidemiological and therefore, have not reported 
the ocular complications and sequelae of the 
disease which are challenging for patients.14–17 
In this study, out of 384 eyes, 97% of the patients 
had ocular complications, which is comparable to 
results in Iran (98.53%)18 and India (87%),19 but a 
much higher than that reported in Nepal (57%),20,21 
Brazil (31.5%),22 or South Korea (34%).23 This could 
be explained by the fact that a higher proportion of 
Yemeni patients usually present late for treatment 
and have more limited access to medical care.   
In the present study, the majority of patients were 
males (93.8%), a similar percentage to that noted 
in other studies.20,24,25 However, the male to female 
ratio in this study was 15:1, which is considerably 
higher than that of a study in Nepal21 that reported 
a ratio of 3:1 and a study by Holmes that reported 
a ratio of 2:1.26 In addition to the stigma presented 
by the disease itself, this ratio can be explained by 
the cultural habits and socioeconomics of Yemeni 
people as Yemeni women make use of health 
services less frequently than men.
The mean age of the patients in this study was 
55.4 years which was significantly higher than the 
35.2 years reported in a study done by Wade et al.27 
In the present study, a higher proportion of the 
patients (81.8%) were over 40 years of age, which 
is similar to the earlier observations from Nepal,21 
South Korea,24 and south Vietnam.25 
Gupta et al. reported that ocular lesions were 
seen more frequently with increasing patient age and 
disease duration.28 Similar results were documented 
Table 2: Distribution of ocular findings in leprosy patients according to age and duration of disease
Findings 
N = 384 eyes, (192 
patients)











Lid involvement 30 (7.8) 72 (18.7) 15 (3.9) 36 (9.3) 51 (13.3)
Lagophthalmos 39 (10) 51 (13.2) 12 (3) 33 (8.5) 45 (11.7)
Corneal opacity 30 (7.8) 54 (14.1) 12 (30 33 (8.5) 45 (11.7)
Uveitis 45 (11.7) 33 (8.6) 15 (3.9) 33 (8.6) 30 (7.8)
Cataract 12 (3) 42 (11) 9 (2.3) 15 (3.9) 30. (7.8)
Retinal lesions 3 (.8) 9 (2.3) 0 6 (1.6) 6 (1.6)
Phthisis bulbi 0 6 (1.6) 0 3 (.8) 3 (.8)
Total 159 (41.1) 267 (69.5) 57 (14.8) 156 (40.6) 213 (55.5)
Without lesions 12 (3) 0 9 (2.3) 3 (.8) 0
VA <6/60 6 (1.6) 186 (48.4) 30 (7.8) 24 (6.3) 138 (36)
VA = visual acuity.
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in this study where ocular involvement increased 
with disease duration and patient age. Only 14.8% 
of patients who had had leprosy for <10 years had 
ocular involvement as opposed to 55.5% who had 
had the disease for >20 years. Similar findings were 
reported in Nepal20 and Nigeria.29
Eyelid involvement was the most frequent 
ocular complication observed in this study 
(26.5%). However, the possibility of trachoma as a 
contributing factor cannot be excluded, although 
leprosy itself can cause lid affection. Lagophthalmos 
and corneal opacity were other common ocular 
complications, representing 23 and 21.9% of cases, 
respectively. This finding was similar to a study done 
in Nepal where 45% of patients experienced either 
lagophthalmos or corneal opacity.21 This finding is 
not surprising as leprosy is a granulomatous disease 
primarily affecting the peripheral nerves. Uveitis 
(20%) and cataracts (14%) were the next two most 
common ocular complications observed in this 
study. Cataract was seen with higher frequency 
among patients >40 years (11%) as compared to 
3% in patients of <40 years. This could simply be 
age-related; however, some cataracts may have been 
due to long-term steroid use in severe or recurrent 
leprosy immune reactions, or due to chronic uveitis. 
At the level of the posterior segment we noticed 
only 12 cases (3%). Most of them were not related 
to the disease but showed age-related macular 
degeneration, comparable to the observation by 
Chams et al., who reported macular degeneration 
in 5.2% of patients.18
Lid lesions and lagophthalmos were observed 
with a higher frequency in the right as opposed 
to the left eye, which was statistically significant. 
Moreover, there was a significantly higher percentage 
of uveitis observed in the left eye compared to the 
right one. However, retinal lesions and phthisis 
bulbi were only documented in patients’ left eyes. 
The significant difference in the rate of occurrence 
of ocular complications between right and left eyes 
remains a mystery.   
Among Yemeni patients with ocular 
complications, 50% of eyes were blind which 
is comparable to results in Nepal (48%), and in 
Cameroon (38.3%); however, these rates are much 
higher than those reported by Vedy et al.1 (2–
5%), Sansarricq (5.4%)31 and Nepal et al.21 These 
differences could be due to lack of uniformity in the 
definition of blindness, with blindness being defined 
as VA ranging from <0.1, to <6/60, or <6/120 with 
Table 3: Prevalence of blindness in different ocular 
leprotic lesions (n = 192 eyes)




Cataract 60 (61.3) 24.9–38.4
Uveitis 45 (23.4) 17.8–30.2
Retinal lesions 12 (6.3) 3.0–10.9
Phthisis bulbi 6 (3.1) 1.2–7.0
Table 4: Prevalence of ocular pathologies (OC) and main cause of blindness in different studies of leprosy
Author/year Country Sample Size Prevalence 
of OC in %
Prevalence and 
main cause of 
blindness in %
Ocular Complications
Lamba, 198415 India 650 87.3 CO = 33.6
Lago = 45 
Lago, CO, Cat, Uveits
Lewallen, 200019 Korea 270 34 Cat = 46
CO = 87
Cat, CO, Uveitis, Lago
Mvogo, 200126 Cameroon 218 77.5 Cat = 38.3
Lago = 33.2 
CO, Lago, Lid lesions, Iritis
Nepal, 200417 Nepal 58 57 CS = 48
CO = % unreported
CS, CO, Lago, Uveitis, Cat.
Mpyet, 200525 Nigeria 480 47 Cat = 31.9
Lago = 46
Cat, Lago, CO, Uveitis
Present study Yemen 192 97 CO = 50
Lago = 35.9
Lid lesion, Lago, CO, 
Uveitis, Cat
 CO = corneal opacity; Lago = lagophthalmos; Cat = cataract; CS = corneal sensitivity
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best correction in the better eye.12–30 Out of these 
blind eyes, 37 patients (19%) were completely 
disabled due to binocular blindness. 
Corneal opacity was the commonest cause 
of blindness in this study (69 out of 192 patients; 
35.9%) which is logical as lagophthalmos and lid 
involvement were the most frequent complications; 
they may lead to exposure keratitis, corneal 
ulceration or corneal anaesthesia. Corneal opacity 
was the second commonest cause of blindness among 
leprosy patients in a study done in Nigeria (28%), 
which also confirms that in leprosy the cornea is a 
target organ either indirectly or directly through the 
spread of bacilli by an exogenous, haematogenous, 
or neurogenous route.1,29 Cataracts ranked as the 
second most common cause of blindness (31.3%) in 
this study, while it was the most common cause in 
Nigeria (46%) and South Korea (87%).23–32 In Nepal, 
uveitis with secondary glaucoma was a primary 
cause of blindness in the past but with increased 
knowledge of the disease and its complications, 
and the introduction of new treatments, these 
causes have declined dramatically.20 In contrast, 
in  the current study, uveitis was found to be the 
third most common blinding condition (23.4%). 
This could be explained by the fact that most of the 
patients with chronic cases of uveitis had extremely 
constricted pupils, and treatment to dilate them was 
unsatisfactory due to the atrophy of the iris dilator 
muscles and synechia.
Conclusion
Ocular complications from leprosy are frequent in 
Yemen regardless of the form of leprosy, with lid 
involvement being the most frequent complication. 
Of the 384 eyes examined, 50% were blind due to 
leprosy. Corneal opacity, cataracts, and uveitis were 
the most common causes of this blindness. Since 
ocular involvement occurs late in the course of the 
disease, blinding lesions could be prevented by early 
diagnosis, and prompt and adequate treatment. 
Therefore, all health and paramedical personnel in 
charge of leprosy patients must be trained in the 
basics of the disease and its ocular complications. 
Additionally, a policy should be enacted whereby 
health care providers ensure patient follow-up 
during and after MDT, with periodic ophthalmic 
examinations in leprosaria. Further research should 
be done to relate the ocular complications to the 
type and reactions of leprosy, and to ascertain 
whether released patients are still undergoing MDT.
There is an urgent need for better collaboration 
between leprosy control and blindness prevention 
programmes, and their integration into general 
health services to enable patient access to high 
quality eye care services and to allay unjustified 
fears of leprosy.
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